---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/41475181.md"
description: "Innovent Biologics, WuXi Biologics, and Danuo Pharmaceuticals basically didn't move today — Hong Kong stock innovative drugs and CXO are just this kind of quiet sideways movement 🤔 Innovative drugs have been waiting for the medical insurance negotiation and key clinical data, while CXOs are waiting for visibility into overseas orders. On days without new catalysts, capital is also too lazy to move. Valuation recovery for Hong Kong-listed pharmaceutical stocks often requires a clear data or policy catalyst to ignite it. Buying the dip during the sideways period can easily wear down one's patience — do you think the turning point this time will come first from the medical insurance negotiation or from a recovery in CXO orders?"
datetime: "2026-06-04T10:52:36.000Z"
locales:
  - [en](https://longbridge.com/en/topics/41475181.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/41475181.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/41475181.md)
author: "[软乎乎的小熊](https://longbridge.com/en/profiles/27330473.md)"
---

# Innovent Biologics, WuXi Biologics, and Danuo Phar…


### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [02269.HK](https://longbridge.com/en/quote/02269.HK.md)
- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)

## Comments (2)

- **ice · 2026-06-05T01:15:35.000Z**: Think about why WuXi AppTec bought Dongyao
- **ice · 2026-06-05T01:14:44.000Z**: By August at the latest, when the earnings report comes out, it will be found to have surged.